Gefitinib Usage and Outcomes in Routine Treatment

AstraZeneca

Status: Completed

Conditions: Lung Cancer

Study type: Observational

Funder types: Industry

Identifiers

NCT01818947

NIS-OGB-IRE-2012/1

Details and patient eligibility

About

The purpose of this study is to understand real world gefitinib usage patterns, patient characteristics and outcomes and to present these for a Caucasian population

Full description

A multicentre, retrospective chart review study to characterise gefitinib usage and outcomes in routine treatment

Enrollment: 157 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients who received gefitinib first line in the UK Single Payment Access (SPA) scheme
• Locally advanced or metastatic EGFR mutation positive NSCLC
• Supplied with first pack of gefitinib prior to 1st January 2012

Exclusion criteria

• Patient was treated privately (i.e. outside the NHS)
• Gefitinib was second-line therapy following treatment failure on a prior therapy

Trial design

157 participants in 1 patient group

Gefitinib